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Interactions between tumor and immune cells either enhance or inhibit cancer progression. We show here
that Stat3 signaling within the tumor microenvironment induces a procarcinogenic cytokine, IL-23, while
inhibiting a central anticarcinogenic cytokine, IL-12, thereby shifting the balance of tumor immunity toward
carcinogenesis. Stat3 induces expression of IL-23, which is mainly produced by tumor-associated macro-
phages, via direct transcriptional activation of the IL-23/p19 gene. Furthermore, Stat3 inhibits NF-kB/c-
Rel-dependent IL-12/p35 gene expression in tumor-associated dendritic cells. Tumor-associated regulatory
T cells (Tregs) express IL-23 receptor, which activates Stat3 in this cell type, leading to upregulation of the
Treg-specific transcription factor Foxp3 and the immunosuppressive cytokine IL-10. These results demon-
strate that Stat3 promotes IL-23-mediated procarcinogenic immune responses while inhibiting IL-12-depen-
dent antitumor immunity.
INTRODUCTION
The transcription factor Stat3 is constitutively activated in diverse
cancers (Yu and Jove, 2004), and its activation in tumors
enhances transcription of genes associated with cell-cycle
progression, cell survival, angiogenesis, and immune evasion
(Yu and Jove, 2004; Yu et al., 2007). In addition to tumor cells,
Stat3 is constitutively activated within many immune cell types
in the tumor microenvironment, including dendritic cells (DCs)
and macrophages (Kortylewski et al., 2005). Ablating Stat3 in
myeloid cells allows efficient CD8+ T cell infiltration into tumors
while inhibiting accumulation of regulatory T cells (Tregs) (Korty-
lewski et al., 2005). Activated Stat3 suppresses antitumor
immunity by inhibiting the expression ofmany cytokines and che-
mokines important for stimulating antitumor immunity and by
upregulating production of several immunosuppressive factors,
including IL-10 and VEGF (Takeda et al., 1999; Wang et al.,
2004). These immunosuppressive factors are not only Stat3
target genes but also Stat3 activators (Yu et al., 2007). In order
to further explore the mechanisms by which Stat3 mediates
tumor immunosuppression,we evaluated its role in the regulation
of two closely related cytokines, IL-23 and IL-12, which play
critical but opposing roles in tumor immunity.
IL-12, a heterodimer composedofa and b subunits (termedp35
and p40, respectively), promotes antitumor immunity via activa-
tion of natural killer (NK) cells and T helper 1 (Th1) T cells and is
characterized by production of interferon-g, another important
cytokine in antitumor immunity (Gerosa et al., 2002; Kaplan
et al., 1998; Shankaran et al., 2001; Trinchieri, 2003). IL-12 further
promotes the expansion and activity of cytotoxic T lymphocytes
(CTLs) both directly and indirectly by Th1 cells (Colombo and Trin-
chieri, 2002). IL-23, a more recently discovered IL-12 family
member, is composed of the p40 subunit in common with IL-12,
pairedwith a unique p19 subunit (Oppmann et al., 2000). Similarly,
IL-12 receptor (IL-12R) and IL-23 receptor (IL-23R) share
a common b subunit, which is paired with a unique a subunit for
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Stat3 Regulates IL-23/IL-12 Balance in Tumorseach receptor (Parham et al., 2002). While IL-23 was originally
thought to possess proinflammatory properties similar to IL-12,
analysis of mice with selective knockout of the IL-12/p35 gene
versus the IL-23/p40 gene revealed distinct functions for these
two cytokines. In particular, a number of experimental autoim-
mune diseases were shown to be dependent on IL-23 and not
on IL-12 (Cua et al., 2003; Ghilardi et al., 2004; Langrish et al.,
2005;Murphy et al., 2003). IL-23 has also been shown to promote
the expansion of a distinct lineage of helper T cell, termed Th17
(Langrish et al., 2005). Th17 cells are characterized by production
ofanumberofspecificcytokinesnotproducedbyTh1orTh2cells,
including IL-17A, IL-17F, IL-21, and IL-22. Interestingly, Stat3 has
also been documented to be an essential transcriptional regulator
of IL-17, IL-21, and IL-22 production by Th17 cells (Chen et al.,
2006; Harris et al., 2007; Laurence et al., 2007; O’Shea and Mur-
ray, 2008; Wei et al., 2007; Zheng et al., 2007; Zhou et al., 2007).
An opposite role in carcinogenesis has recently been reported
for IL-23 compared to IL-12 (Langowski et al., 2006, 2007).
Carcinogen-induced tumor formation was greater in IL-12/p35
KO mice, confirming the physiologic antitumor role of IL-12;
however the opposite effect was observed in IL-23/p19 KO
mice (Langowski et al., 2006). Whereas IL-12 facilitated tumor
Figure 1. IL-23 and IL-12 Expression in Tumor-
Infiltrating Myeloid Cells Is Compartmentalized and
Oppositely Regulated by Stat3
(A and B) ELISA measurement of protein levels of IL-23 (A) and
IL-12 (B) in supernatants of tumor cell lines (B16 and C4 mela-
noma cells), B16whole tumor cell suspensions (total tumor), en-
riched tumor-infiltratingCD11b+CD11cmacrophages (MACs),
and CD11c+ dendritic cells (DCs) cultured in vitro for 24 hr from
mice with Stat3+/+ or Stat3/ hematopoietic cells. Data shown
are mean values ± SD from one of three separate experiments
performedoncellspooled from fouranimalspergroupanalyzed.
(C)Western blot detection of IL-23/p19 protein levels in CD11b+
cells isolated fromwhole B16 tumors and tumor-draining lymph
nodes (TDLN) of Stat3+/+ or Stat3/ mice.
(D and E) IL-23 and IL-12 protein levels measured by ELISA as
in (A), in supernatants from enriched tumor-infiltrating
CD11b+CD11c MACs and CD11c+ DCs isolated from whole
MC38 colon carcinoma (D) and MB49 bladder carcinoma (E)
tumors. Data are mean ± SEM (n = 3).
infiltration of CD8+ T cells, IL-23 reduced CD8+
T cells in tumor and promoted tumor angiogenesis
(Langowski et al., 2006). While these results
suggest a procarcinogenic role for IL-23 production
within tumors, its mechanisms of action in tumor
regulation have not been elucidated. We therefore
investigated how IL-23 and IL-12 expression are
differentially regulated in the tumor microenviron-
ment and how IL-23 further propagates tumor
immunosuppressive effects.
RESULTS
Role of Stat3 in the Differential Expression
of IL-23 and IL-12 in Tumors
We assessed IL-23 and IL-12 protein secretion by
B16 tumor cells in vitro and B16 tumors growing
in vivo after implantation into C57BL/6 mice. B16 tumor cells
and a second melanoma tumor line, C4, cultured in vitro
secreted very little of either cytokine as detected by ELISA
(Figure 1A, left). B16 tumors growing in vivo were dissociated
into single-cell suspensions that consisted of tumor cells as
well as hematopoietically derived cells comprising the tumor
microenvironment. Similar to in vitro results, only a small amount
of IL-23 or IL-12 secretion was detected by ELISA when the
unfractionated cell suspensions were cultured (Figures 1A and
1B, left). When the tumor-associated myeloid component was
sorted by fluorescence-activated cell sorting (FACS) into macro-
phages (CD11b+c) and DCs (CD11b+c+), high levels of IL-23
were found to be produced by the tumor-associated macro-
phages (MACs; Figure 1A, middle), with much lower levels
produced by tumor-infiltrating DCs (Figure 1A, right). Western
blot data demonstrated that IL-23 was also detectable in
CD11b+ cells isolated from tumors and tumor-draining lymph no-
des (Figure 1C). Virtually no IL-12 was secreted either by unfrac-
tionated tumors or by purified tumor-associated macrophages
or splenic DCs as determined by ELISA (Figure 1B).
The role of Stat3 signaling in IL-23 and IL-12 regulation
within the tumor microenvironment was initially determined by
Cancer Cell 15, 114–123, February 3, 2009 ª2009 Elsevier Inc. 115
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compartment. To accomplish this, Mx1-Cre/Stat3flox/flox mice
were treated with polyinosinic:polycytidylic acid (poly(I:C)). We
have previously demonstrated that Stat3 is efficiently knocked
out in myeloid cells under these conditions (Kortylewski et al.,
2005). By 24 hr after poly(I:C) treatment, there was no evidence
of residual activation of either DCs ormacrophages asmeasured
by either cell membrane markers or cytokine production
(Kortylewski et al., 2005). To avoid any confounding effects of
immunostimulation by poly(I:C) treatment, Mx1-Cre/Stat3flox/flox
and control Stat3flox/flox littermate mice were not challenged
with tumors until 4 days after completion of poly(I:C) treatment.
IL-12 and IL-23 production in tumors was analyzed 2–3 weeks
later. We purified macrophages and DCs in tumors grown in
poly(I:C)-treated Mx1-Cre/Stat3flox/flox mice with induced Stat3
ablation, as well as poly(I:C)-treated Stat3flox/flox control mice.
Hematopoietic Stat3 ablation significantly reduced IL-23
production by B16 tumor-associated macrophages (Figure 1A).
In contrast, IL-12 production was upregulated in B16 tumors
from mice with hematopoietic Stat3 knockout. The majority of
IL-12 expression came from the tumor-associated DCs infil-
trating B16 tumors (Figure 1B). Thus, these data implied that
Stat3 signaling drives IL-23 production from the tumor-associ-
ated macrophages while restraining IL-12 production by
tumor-associated DCs. This effect was specific for the tumor
microenvironment since there was no significant production of
either IL-12 or IL-23 by splenic macrophages or DCs regardless
of whether the Stat3 gene was ablated.
To test the generality of our findings that Stat3 in tumor stromal
myeloid cells contributed to regulating IL-23 and IL-12 expres-
sion in tumors, we performed similar experiments using MC38
colon carcinoma (Figure 1D) and MB49 bladder carcinoma (Fig-
ure 1E) models. In vivo experiments showed that the growth of
MC38 tumors was inhibited by Stat3 ablation in myeloid cells
(see Figure S1 available online), confirming previous data in
B16 and MB49 tumor models (Kortylewski et al., 2005). Consis-
tent with our results in the B16 tumor model, ablating Stat3 in
myeloid cells decreased production of IL-23 by macrophages
within MC38 and MB49 tumors (Figures 1D and 1E). While the
overall level of IL-23 secretion by MC38 and MB49 tumor-
infiltrating macrophages in control Stat3flox/flox mice was lower
than that observed in B16 tumors, the IL-23 that was produced
was clearly Stat3 dependent. Likewise, the DCs isolated from
MC38 and MB49 tumors showed increased secretion of IL-12
following induced Stat3 ablation. The level of IL-12 secretion
by DCs isolated from MC38 and MB49 tumors did not reach
the levels observed in the B16 tumor model, but the increases
observed with hematopoietic Stat3 knockout were highly repro-
ducible. Multiple factors likely contribute to the differences in
magnitude of IL-23 and IL-12 production by tumor-associated
macrophages andStat3/ tumor-associated DCs, respectively,
in the different tumors. Previous studies indicated that IL-12
expression can be induced in Stat3/ splenic DCs by Toll-like
receptor (TLR) activation (Kortylewski et al., 2005). Dying tumor
cells have also been shown to stimulate DC IL-12 production
(Apetoh et al., 2007). The presence of large necroses (up to
89% of tumor area) within B16 tumors (Garcia-Hernandez
et al., 2002), which was not observed in MC38 or MB49 tumors
(M. Kortylewski and H. Yu, unpublished data), might provide
cell debris capable of costimulating intratumoral DCs to produce
IL-12 after deletion of Stat3.
Stat3 Directly Regulates IL-23/p19 Transcription
In order to determine themechanism for regulation of these cyto-
kines by Stat3 in the tumor microenvironment, we first analyzed
IL-23/p19 gene regulation. Stat3 ablation indeed reduced IL-
23/p19 mRNA in tumor-associated macrophages by roughly
10- fold, with virtually no IL-23/p19mRNA detectable in Stat3+/+
or Stat3/ splenic macrophages (Figure 2A). Despite low levels
(26- and79-fold lower inB16andC4cells, respectively, relative to
tumor-infiltrating macrophages), IL-23/p19 mRNA in the tumor
cells was reduced more than 80% by Stat3 siRNA knockdown
(Figure S2A). These results suggested that Stat3 positively regu-
lates IL-23 at the transcriptional level in different cell types. In
order to determine whether this transcriptional regulation was
direct, we performed luciferase reporter and chromatin immuno-
precipitation (ChIP) analyses. First, 3T3 cells were transfected
with a luciferase expression vector driven by the IL-23/p19
promoter (1159 to +160). Dual-luciferase activitywasenhanced
significantly by cotransfection with a constitutively active Stat3
mutant, Stat3C (Figure 2B). B16 cell transfection with the IL-23/
p19 promoter-driven luciferase reporter gene resulted in
progressively decreased luciferase activity with successively
increasing amounts of Stat3 siRNA (Figure 2C, top). Cotransfec-
tion with NF-kB/p65 siRNA also resulted in decreased luciferase
activity, with the greatest suppression occurring upon cotrans-
fection with both Stat3 and NF-kB siRNAs (Figure 2C, bottom).
These results indicate that NF-kB/p65, which is also constitu-
tively activated in B16 like in many other cancers, participates
in IL-23/p19 transcription.
Wenext performedChIPanalysis onB16cells usingprimers for
the IL-23/p19 promoter. Both Stat3 and NF-kB/p65were associ-
atedwith the IL-23/p19promoter (Figure 3A).While it was difficult
to obtain enough tumor-associated macrophages to perform
ChIP analysis, ChIP of total tumors growing in vivo as well as
tumor-draining lymph nodes demonstrated Stat3 binding to the
IL-23/p19 promoter along with NF-kB/p65 (Figures 3B and 3C).
NF-kB/p65 binding to the IL-23/p19 promoter was also higher
in tumor-draining lymph nodes relative to nondraining lymph
nodes (Figure 3B). Hematopoietic Stat3 ablation resulted in
a decreased ChIP signal for both Stat3 and NF-kB/p65 on the
IL-23/p19 promoter in growing B16 tumors (Figure 3C).
Stat3 Inhibits NF-kB/c-Rel-Mediated IL-12/p35 Gene
Expression
Real-time PCR demonstrated that Stat3 reciprocally downregu-
lated IL-12/p35 transcription in whole B16 tumors growing in
hematopoietic Stat3 KO mice (Figure 4A, left), in tumor-associ-
ated myeloid cells (Figure 4A, right), and in cultured B16 tumor
cells after siRNA transfection (Figure S2B). The NF-kB family
transcription factor c-Rel has been demonstrated to be essential
for transcription of IL-12/p35 (Grumont et al., 2001) and other
genes important for DC activation (Wang et al., 2007). However,
we found that levels of active c-Rel were low in growing tumors
(Figure 4B). Upon hematopoietic Stat3 ablation, there was
increased c-Rel activity (phospho-c-Rel) in tumors (Figure 4B,
left), as well as increased binding to the IL-12/p35 promoter of
116 Cancer Cell 15, 114–123, February 3, 2009 ª2009 Elsevier Inc.
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ablation did not affect p65 binding to the IL-12/p35 promoter.
IL-23R and Stat3 Signaling in Tumor-Infiltrating Tregs
An immunosuppressive role for Stat3 in myeloid cells in the
tumor microenvironment has been demonstrated in Mx1-Cre/
Stat3flox/flox mice (Kortylewski et al., 2005). However, whether
intrinsic Stat3 signaling in T cells mediates tumor immunosup-
pression has not been shown. To address this question, we
next determined the role of Stat3 and IL-23 in T cell physiology
within the tumor microenvironment. Tumor growth is enhanced
by the CD4+Foxp3+ Treg subset, which produces cytokines
such as IL-10 and TGF-b and antagonizes Th1- and CD8-medi-
ated antitumor responses (Zou, 2006). As has been found in
several other tumors, the major subset of CD4+ T cells infiltrating
growing B16 tumors (>50%) are Foxp3+ Treg cells (Kortylewski
et al., 2005). Analysis of B16 tumor Tregs by intracellular staining
of phospho-Stat3 (pStat3) demonstrated that Stat3 was consti-
tutively activated in tumor-infiltrating Tregs relative to their
splenic counterparts from the same mice (Figure 5A, top). Since
IL-23R is known to signal through Stat3, we tested whether
tumor CD4+Foxp3+ Tregs express detectable IL-23R in B16
tumors. Whereas splenic Tregs did not express detectable
IL-23R, Tregs fromboth tumors and tumor-draining lymph nodes
were positive for IL-23R (Figure 5A, bottom). Elevated expres-
sion of IL-23R in Tregs from tumors and tumor-draining lymph
Figure 2. Stat3 and NF-kB/p65 Synergistically Enhance IL-23
Expression by Directly Binding to the IL-23/p19 Promoter
(A) Stat3 upregulates expression of IL-23/p19 mRNA in CD11b+ myeloid cells
freshly isolated from B16 tumors. Shown are the results from one of three
independent experiments analyzed by real-time PCR, normalized to 18S
rRNA.
(B) Overexpression of a constitutively active Stat3 mutant (Stat3C) activates
transcription by the IL-23/p19 promoter. The fragment from the mouse
IL-23/p19 promoter (1159 to +160) was cloned into pGL3 vector with a lucif-
erase reporter gene. Dual-luciferase activity was determined 24 hr after
transfection of various sets of expression vectors into 3T3 fibroblasts.
(C) Stat3 and NF-kB/p65 regulate the p19 promoter. Top: Stat3 silencing
downregulates the activity of the IL-23/p19 promoter. Dual-luciferase activity
was measured in lysates of B16 cells 24 hr after transfection with various
concentrations of Stat3 siRNA or with scrambled RNA control. Bottom: both
Stat3 and NF-kB/p65 transcription factors are required for the transcriptional
activity of the IL-23/p19 promoter. Stat3 siRNA, NF-kB/p65 siRNA, or both
were transfected into B16 cells together with IL-23/p19 promoter-luciferase
construct. Dual-luciferase activity was measured as described above.
Data shown are mean values ± SD from experiments performed in triplicate.
Figure 3. Both Stat3 and NF-kB/p65 Bind to the IL-23/p19 Promoter
(A) B16 tumor cells were transfected with pRV-CMV Stat3-FLAG or control
vector, and antibodies specific for control IgG (PIS), Stat3, NF-kB/p65, or
FLAG-M2 as indicated were used for chromatin immunoprecipitation (ChIP).
Chromatin was purified and amplified by PCR using primers specific for
Stat3 and NF-kB binding sequence of the mouse IL-23/p19 promoter.
(B) Binding of Stat3 and NF-kB/p65 to the IL-23/p19 promoter is elevated in
tumor-draining lymph nodes (TDLN), but not in distant lymph nodes. Cells iso-
lated from pooled tumor-draining or contralateral lymph nodes were fixed with
formaldehyde and subjected to ChIP assay performed as described above.
(C) Tumors from mice with myeloid cell-specific Stat3 ablation show reduced
Stat3 and NF-kB/p65 binding to the IL-23/p19 promoter as assessed by ChIP
assay.
Cancer Cell 15, 114–123, February 3, 2009 ª2009 Elsevier Inc. 117
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models (Figure 5A, bottom). Furthermore, although recombinant
IL-23 did not induce Stat3 activation in splenic Tregs, the already
evident endogenous pStat3 of the tumor Tregs could be further
upregulated by addition of recombinant IL-23 in vitro (Figure 5B).
These results demonstrated that tumor-associated Tregs are
distinct from peripheral Tregs in that they express functional
IL-23R and that IL-23R signals in part through Stat3.
In order to assess the role of Stat3 activity in tumor-infiltrating
T cells in vivo, we introduced B16 tumors into CD4-Cre/
Stat3flox/flox mice, which selectively ablate Stat3 in the T cell
compartment. Figure 6A shows that tumor-infiltrating Tregs
from wild-type mice contained significant amounts of pStat3,
while no pStat3 was detected in tumor-infiltrating Tregs from
CD4-Cre/Stat3flox/flox mice. Consistent with an important role
for Stat5 in maintaining Tregs (Yao et al., 2007), we found that
B16 tumor-infiltrating Tregs also displayed high Stat5 activity
(Figure 6A). Since IL-23 is known to stimulate both Stat3 and
Stat5 (Parham et al., 2002), the finding that tumor Tregs express
functional IL-23R suggests that Stat3-dependent expression of
IL-23 in the myeloid compartment can promote tumor growth
through an autoamplification mechanism involving activation of
both Stat3 and Stat5 in IL-23R+ tumor-infiltrating Tregs. In mice
withStat3/ T cells, Foxp3+ Tregswere still the dominant tumor-
infiltrating CD4 subset; however Foxp3 levels were reduced
relative to tumor-bearing wild-type mice (Figure 6B). Further-
more, tumor-infiltrating Tregs from CD4-Cre/Stat3flox/flox mice
produced significantly less IL-10 than tumor-infiltrating Tregs
from their Stat3+/+ counterparts (Figure 6C). Consistent with
previous reports on the absolute requirement for Stat3 in Th17
development in vivo (Harris et al., 2007; Wei et al., 2007; Zhou
et al., 2007), Th17 cells (as defined by intracellular cytokine stain-
ing for IL-17) were completely absent in CD4-Cre/Stat3flox/flox
mice, while Th1 cells (as defined by intracellular cytokine staining
for IFN-g) were unaffected (Figure 6D).
Effects of IL-23R Blockade on Tumor Tregs
and Tumor Growth
Because IL-23R signals through Stat3 (Parham et al., 2002) and
Stat3 can affect expression of Foxp3 and IL-10 in CD4+ T cells
(Kinjyo et al., 2006; Pallandre et al., 2007; Yao et al., 2007), we
Figure 4. Stat3 Inhibits IL-12/p35 Gene Expression
(A) Stat3 knockdown or ablation augments IL-12/p35 expression in whole
tumors (left) and in tumor-infiltrating myeloid cells (right). Data are mean ± SD
(n = 3).
(B) Stat3 inhibits c-Rel activity and binding of c-Rel to the IL-12/p35 promoter
in tumors. Left: western blot analysis of c-Rel phosphorylation after immuno-
precipitation of total c-Rel from spleens and tumors of mice with Stat3+/+
and Stat3/ hematopoietic compartments. Right: ablating Stat3 in hemato-
poietic cells increases binding of NF-kB/c-Rel, but not NF-kB/p65, to the
IL-12/p35 promoter in whole tumor preparations as measured by ChIP assay.
Figure 5. IL-23 Receptor and Stat3 Signaling in Tumor Regulatory
T Cells
(A) Stat3 is activated in tumor regulatory T cells (Tregs), which are IL-23R
positive. Cell suspensions prepared from spleens and from tumors as well
as tumor-draining lymph nodes were subjected to flow analyses for phos-
pho-Stat3 (top panel) and IL-23R (bottom three panels).
(B) Recombinant IL-23 can further activate Stat3 in CD4+Foxp3+ lymphocytes
derived from tumors but not spleens. Shown are representative results from
2–3 independent experiments.
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tumormicroenvironment andwhether this directly enhances B16
tumor growth in vivo. IL-23R blockade affected tumor-infiltrating
Tregs in a manner similar but not identical to T cell-specific Stat3
ablation (Figures 7A and 7B). Anti-IL-23R-treatedmice displayed
amodest but significant reduction in number of tumor-infiltrating
Tregs compared with control antibody-treated mice. However,
Foxp3 levels were diminished after anti-IL-23R treatment
(Figure 7A, right), as was IL-10 production (Figure 7B). While
these results are consistent with a role for IL-23-driven Stat3
activation in tumor-infiltrating Tregs, additional IL-23R-depen-
dent signaling pathways (such as Stat5) are likely operative in
tumor-infiltrating Tregs. In addition, other cytokines in the tumor
microenvironment (such as IL-10) could additionally contribute
to Stat3 activation in tumor-infiltrating Tregs. The effects of IL-
23 within the tumor microenvironment indeed translate to an
overall enhancement of tumor growth, as in vivo IL-23R blockade
resulted in a significant reduction in tumor growth relative to
isotype control antibody (Figure 7C).
DISCUSSION
The immune system acts as an extrinsic tumor suppressor (Dunn
et al., 2005; Kaplan et al., 1998; Koebel et al., 2007). However,
Figure 6. The Effects of Stat3 Ablation on Tumor-
Infiltrating Tregs
(A) Stat3 ablation does not significantly affect Stat5 activity in
tumor-infiltrating CD4+Foxp3+ Tregs as measured by intracel-
lular staining with Stat3- and Stat5-phosphospecific anti-
bodies and flow cytometry.
(B) The effect of Stat3 signaling in tumor CD4+ T cells on the
number of Foxp3+ cells (left) and expression levels of Foxp3
(right), using CD4+ T cells prepared from B16 tumors grown
in Stat3flox/flox (Stat3+/+) and CD4-Cre/Stat3flox/flox mice. Data
shown at left are mean ± SEM; NS, not significant. The repre-
sentative histogram at right shows one of three independent
experiments with total n = 12.
(C) Lower expression of IL-10 by tumor-derived CD4+CD25+
Tregs from Stat3/ mice. The two panels at the left show
representative results for three independent experiments.
The bar graph at right combines data from three independent
experiments with total n = 12 and shows mean ± SEM;
p = 0.0103.
(D) The two panels at the left show intracellular expression of
IFN-g and IL-17 cytokines by tumor-infiltrating Stat3+/+ and
Stat3/ CD4+ T cells as assessed by intracellular staining
and flow cytometry using freshly isolated whole tumor cell
preparations. The two bar graphs at the right represent three
independent experiments with total n = 12. NS (not significant)
and p < 0.0001, respectively. Data shown are means ± SEM.
tumors acquire various mechanisms to facilitate
immune escape (Dunn et al., 2002; Zou, 2005).
Our results demonstrate that Stat3 signaling in the
tumor microenvironment shifts inflammation from
an antitumor IL-12 program to a tumor-enhancing
IL-23 program via transcriptional activation of the
IL-23-specific p19 gene and concomitant transcrip-
tional suppression of the IL-12-specific p35 gene.
Stat3 appears to coactivate the p19 promoter
with NF-kB/p65. In contrast, Stat3 also appears to suppress
c-Rel in tumors, thereby reducing binding of c-Rel to the IL-12/
p35 promoter. This is in agreement with a recent report indicating
that NF-kB subunits have unique roles in regulating gene expres-
sion in DCs (Wang et al., 2007). The p50 and c-Rel subunits were
found to be critical for the induction of T cell stimulatory gene
expression, whereas the NF-kB/p65 subunit regulated expres-
sion of a distinct group of inflammatory genes, some of which
areprocarcinogenic (Wanget al., 2007).WhileStat3 transcription-
ally activates the IL-23/p19 gene in both tumor cells and myeloid
cells within the tumor microenvironment, the major source of
Stat3-driven IL-23 is tumor-associated macrophages. Stat3
restrains IL-12 transcription inboth tumorsand infiltratingmyeloid
cells, though the majority of IL-12-producing cells in the absence
of Stat3 activity are tumor-associatedDCs. It is notable that,while
these effects of Stat3 are not observed systemically, they appear
to be operative in tumor-draining lymph nodes. We are currently
testing the hypothesis that a preponderance of IL-23 production
relative to IL-12 production by antigen-presenting cells in
tumor-draining lymph nodes ultimately skews the differentiation
of tumor-specific T cells, possibly leading to dominance of Treg
and Th17 responses over antitumor Th1 responses.
IL-12 has been validated in numerous studies as a central
cytokine in antitumor immunity and antiviral immunity due to its
Cancer Cell 15, 114–123, February 3, 2009 ª2009 Elsevier Inc. 119
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2003). The emergence of a second IL-12 family member, IL-23,
which shares the p40 subunit with IL-12, has significantly altered
our view of autoimmune disease since a number of murine auto-
immune syndromes originally thought to be IL-12 dependent
are instead IL-23 dependent. These more recent studies have
suggested that IL-12-driven immunity is not only qualitatively
distinct from IL-23-driven immunity but may also be mutually
antagonistic. This notion also pertains to tumor immunity as
emphasized by Langowski et al. (2006), who showed that tumor-
igenesis is diminished in IL-23/p19 KO mice and increased in
IL-12/p35 KO mice. The studies presented here support the
notion that IL-23 has a procarcinogenic role in contrast to the
well-established anticarcinogenic role of IL-12. Importantly, our
findings indicate that Stat3 signaling in both the tumor and the
hematopoietic/immune microenvironment of the tumor is critical
in shifting the balance from IL-12 to IL-23 production.
An additional unexpected finding of our study was the upre-
gulation of IL-23R in tumor-associated Tregs. Although the
underlying mechanism responsible for IL-23R upregulation in
tumor-associated Tregs remains to be elucidated, our limited
data indicate that the increase in IL-23R expression in tumor
Tregs correlates with Stat3 activity. In addition to its central
role in IL-23 upregulation, Stat3 appears to also play a role in
IL-23R signaling within the tumor microenvironment. The role
for Stat3 signaling in IL-10 production by Tregs has not been
Figure 7. Blocking IL-23R Signaling In Vivo Affects
Tumor Tregs and Tumor Growth
Mice were challenged with B16 tumors injected subcutane-
ously and treated with IL-23R-specific neutralizing antibodies
or rat IgG2b control antibodies.
(A) Blocking IL-23 signaling reduces the number of tumor-
infiltrating Tregs (left), and especially the expression level of
Foxp3 (right).
(B) IL-23R neutralization reduces IL-10 production by
CD4+CD25+ Tregs. Phenotypic analysis of tumor-infiltrating
CD4+ T cells was accomplished by cell surface/intracellular
staining with specific antibodies and flow cytometry. For
both (A) and (B), representative results of FACS analysis
from one of two independent experiments are shown. Bar
graphs show means ± SEM with total n = 7. p < 0.0001 (A),
p = 0.0003 (B).
(C) Effects of IL-23R blockade on B16 tumor growth.
Combined results of two independent experiments are shown
as means ± SEM with total n = 10. ***p < 0.001, **p < 0.01.
previously appreciated, although a recent report
demonstrates that IL-27-driven IL-10 production
by T cells is Stat3 dependent (Stumhofer et al.,
2007). While T cell-specific Stat3 ablation also
diminished the number of tumor-infiltrating Th17
cells, this cell population is relatively minor in the
B16 system. Recent studies have indicated that
Th17 can contribute to tumor progression (Kryczek
et al., 2007); however, it appears that, at least with
B16 melanoma, the major role of T cell-specific
Stat3 signaling (and also IL-23R signaling) lies
within the Treg compartment. Indeed, ablation of
Tregs has been shown to significantly enhance
antitumor responses in B16 melanoma (Sutmuller et al., 2001;
Turk et al., 2004). Whether IL-23R-dependent Stat3 signaling
has a larger role in Th17 responses in other tumor systems
remains to be determined. IL-23R signals through multiple other
Stats, which also undoubtedly play a role in how IL-23 modu-
lates the tumor microenvironment. For example, IL-23R also
activates Stat5, which O’Shea and colleagues demonstrated
to be very important in Treg expansion and possibly also differ-
entiation (Yao et al., 2007). Indeed, tumor-infiltrating Tregs have
high levels of tyrosine-phosphorylated Stat5. In this context, it
was somewhat surprising that Stat3 signaling appears to
enhance Foxp3 expression by tumor-infiltrating Tregs. This
finding contrasts with studies suggesting that Stat3 activation
(driven by IL-6 or IL-27) inhibits differentiation to the Treg
lineage (Huber et al., 2008; Laurence et al., 2007). However,
the role of Stat3 in Foxp3 gene regulation may be quite distinct
in tumor-infiltrating Tregs (where the cytokine milieu and
ambient signals are quite distinct) versus naive T cells being
induced into various differentiation pathways in vitro. Indeed,
Pallandre et al. (2007) have demonstrated that, similar to our
findings here, Stat3 ablation decreases Foxp3 expression by
Tregs in a graft-versus-host disease model. Zorn et al. (2006)
showed that both Stat3 and Stat5 can bind to a Stat consensus
site in the Foxp3 promoter. Thus, the role of Stat3 in regulating
Foxp3 expression by Tregs appears to be context dependent.
In the context of the signals present within the tumor
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Foxp3 levels, which Flavell and colleagues have shown to be
important in maintaining Tregs’ inhibitory functions (Wan and
Flavell, 2007).
It should also be emphasized that in addition to IL-23, at least
two other cytokines, IL-6 and IL-10, appear to play an important
role in enhancing cancer progression (Yu et al., 2007). These
cytokines are somewhat interlinked in that they are all Stat3
inducible and their receptors activate Stat3 (O’Shea andMurray,
2008). While much has been written about the role of IL-6 and
IL-10 in promoting tumorigenesis and inhibiting antitumor immu-
nity, our data focus attention on IL-23 as an important mediator
of procarcinogenesis by Stat3 signaling.
EXPERIMENTAL PROCEDURES
Cells
Mouse B16 melanoma cells were purchased from the American Type Culture
Collection. Mouse C4 melanoma, MB49 bladder carcinoma, and MC38 colon
carcinoma cells were generous gifts from J. Fidler (MD Anderson Cancer
Center), T. Ratliff (University of Iowa), and M. Shurin (University of Pittsburgh),
respectively. DC2.4 cells were originally obtained from K. Rock (University
of Massachusetts Medical School). The generation of v-Src-transformed
BALB/c 3T3 fibroblasts has been described previously (Wang et al., 2004).
In Vivo Experiments
Mice were maintained and experimental procedures were performed under
pathogen-free conditions in accordance with established institutional guide-
lines and approved protocols from the Research Animal Care Committees of
the City of Hope and Johns Hopkins University. We obtained Mx1-Cre mice
from The Jackson Laboratory, CD4-Cre mice from Taconic, and Stat3flox/flox
mice from S. Akira and K. Takeda (Osaka University). All transgenic mice
were on a C57BL/6J background. Generation of mice with Stat3/ hemato-
poietic cells by the inducible Mx1-Cre recombinase transgenic system
has been described previously (Kortylewski et al., 2005). We generated
CD4-Cre/Stat3flox/flox mice by standard interbreeding procedures. We verified
specific Stat3 deletion in T cells by PCR using primer sets that distinguish
Stat3, Stat3loxP, and Stat3-deleted alleles and by FACS analysis of Stat3
phosphorylation in IL-6-treated T cells. For tumor challenge, we injected 1 3
105 B16 or 5 3 105 MB49 or MC38 tumor cells subcutaneously into 7- to
8-week-old wild-type or transgenic mice, and tumor growth was monitored
three times per week. For IL-23R neutralization experiments in vivo, mice
were treated with 250 mg of anti-IL-23Ra antibodies (R&D Systems) injected
intraperitoneally every third day during the course of the experiment, starting
from the day of tumor inoculation. Mice were sacrificed 2 weeks after tumor
inoculation. We prepared single-cell suspensions of spleen, lymph node, or
tumor tissues by mechanic dispersion followed by collagenase D/DNase I
treatment as described previously (Kortylewski et al., 2005).
Cytokine ELISA and Western Blotting
We enriched CD11b+c+ or CD11b+c immune cell subsets from spleens and
tumors from Stat3+/+ and Stat3/ (Mx1-Cre/Stat3flox/flox) mice using specific
antibodies in combination with magnetic nanoparticles from StemCell Tech-
nologies as described previously (Kortylewski et al., 2005). For IL-12 and
IL-23 measurement by ELISA (eBioscience), we cultured the enriched cell
populations for 24 hr to collect supernatants. Equal protein amounts of lysates
prepared from enzymatically digested tumors and/or tumor-draining lymph
nodes were analyzed by western blotting using antibodies specific to IL-23/
p19 (R&D Systems), phospho-S503-c-Rel (Thermo Scientific), and b-actin
(Sigma).
Quantitative Real-Time PCR
We isolated total RNAs from various cell populations using the RNeasy System
(QIAGEN) and then transcribed them into cDNAs using the iScript cDNA
Synthesis Kit (Bio-Rad). PCR reactions were set up using specific primer pairs
for mouse IL-23/p19 (50-TCCCTACTAGGACTCAGCCAACTC-30 [forward] and
50-ACTCAGGCTGGGCACTG-30 [reverse]) or commercially available primers
for mouse IL-12/p35, 18S rRNA, or GAPDH (SuperArray). Sequence-specific
amplification was assessed by measuring the fluorescent signal of SYBR
green using a Chromo4 Real-Time PCR Detector (Bio-Rad).
Reporter Gene Assays
We inserted the mouse IL-23/p19 promoter fragment (1159 to +160) into the
XhoI/HindIII site of the pGL3-Basic vector by PCR, generating the pGL3-p19-
Pro-luciferase plasmid. For luciferase assays, we cotransfected 0.4 mg/ml
pGL3-p19-Pro-luciferase plasmid containing 0.02 mg/ml pRL-TK normaliza-
tion construct and 0.4 mg/ml of either the indicated pRC plasmid or siRNAs
(80 pmol/ml) into BALB/c 3T3 fibroblasts and B16 and C4 mouse melanoma
cells using Lipofectamine 2000 (Invitrogen). We analyzed luciferase activity
in whole-cell lysates using the Dual-Luciferase Reporter Assay System (Prom-
ega) and quantified results using a Mikrotek Laborsysteme microplate reader.
Data are presented as firefly luciferase activity normalized to Renilla luciferase
activity in each triplicate sample.
Chromatin Immunoprecipitation Assays
We performed chromatin immunoprecipitations using a ChIP assay kit
(Upstate Biotechnology) according to the manufacturer’s protocol. Briefly,
cultured cells were fixed with 1% formaldehyde at 37C for 10min before lysis.
For ChIP assays on freshly isolated whole tumors or tumor-draining or distant
lymph nodes, prior to crosslinking with formaldehyde, tissues were frozen in
liquid nitrogen and homogenized to enable nuclei isolation. We incubated
the sonicated chromatin solutions with 2 mg of Stat3-, p65-, or c-Rel-specific
antibodies (Santa Cruz) or with control rabbit IgG. Following immunoprecipita-
tion and reversed crosslinking, DNAwas extracted and analyzed by PCR using
the following primer sets: mouse IL-23/p19 promoter, 50-GGATTCCCGTCCCT
CGGTCTC-30 (forward) and 50-GGGCCAAGGCGCTTGGCACAG-30 (reverse);
mouse IL-12/p35 promoter, 50-GACAGTGGAGGCACCAGGCC-30 (forward)
and 50-CAGACATCGCTGTCCCGGCG-30 (reverse).
Flow Cytometry
For extracellular staining of immune markers, we prepared single-cell suspen-
sions by mechanic dispersion and enzymatic digestion of spleen, lymph node,
or tumor tissues.We preincubated 13 106 freshly prepared cells suspended in
amixture of PBS, 2% fetal calf serum, and 0.1% (w/v) sodium azide with FcgIII/
IIR-specific antibody to block nonspecific binding and stained with different
combinations of fluorochrome-coupled antibodies to CD3, CD4, CD25 (BD
Biosciences), or IL-23R (Imgenex). Staining with the anti-IL-23R antibody
required earlier labeling of the unconjugated antibody with a fluorescent dye,
using the Zenon Labeling Kit (Invitrogen). Prior to intracellular staining with
antibodies to phosphotyrosine-Stat3 or -Stat5 (BD Biosciences) and Foxp3
(eBioscience), we fixed cells in paraformaldehyde and permeated them in
methanol. For intracellular staining of IFN-g, IL-10, and IL-17 (BD Pharmingen),
we followed the manufacturer’s protocol after 4 hr incubation in the presence
of Leukocyte Activation Cocktail (BD Pharmingen). Fluorescence data were
collected on a FACSCalibur system (Beckton Dickinson) and analyzed using
FlowJo software (Tree Star).
Statistical Analysis
An unpaired t test was used to calculate two-tailed p values to estimate
statistical significance of differences between treatment groups. Statistically
significant p values are indicated in figures as follows: ***p < 0.001,
**p < 0.01, *p < 0.05. Data were analyzed using GraphPad Prism software.
SUPPLEMENTAL DATA
The Supplemental Data include two figures and can be found with this article
online at http://www.cancercell.org/supplemental/S1535-6108(08)00437-6.
ACKNOWLEDGMENTS
We aremost grateful to S. Akira and K. Takeda (Osaka University) for providing
the Stat3flox mice and the Pathology Core at the City of Hope for technical
assistance. We also acknowledge the dedication of staff members at the
animal facilities and flow cytometry core of the Beckman Research Institute
Cancer Cell 15, 114–123, February 3, 2009 ª2009 Elsevier Inc. 121
Cancer Cell
Stat3 Regulates IL-23/IL-12 Balance in Tumorsat City of Hope National Medical Center. This study was supported by NIH
grant R01 CA122976.
Received: June 10, 2008
Revised: October 8, 2008
Accepted: December 18, 2008
Published: February 2, 2009
REFERENCES
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A.,
Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., et al. (2007). Toll-like receptor
4-dependent contribution of the immune system to anticancer chemotherapy
and radiotherapy. Nat. Med. 13, 1050–1059.
Chen, Z., Laurence, A., Kanno, Y., Pacher-Zavisin, M., Zhu, B.M., Tato, C.,
Yoshimura, A., Hennighausen, L., and O’Shea, J.J. (2006). Selective regulatory
function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad.
Sci. USA 103, 8137–8142.
Colombo, M.P., and Trinchieri, G. (2002). Interleukin-12 in anti-tumor immunity
and immunotherapy. Cytokine Growth Factor Rev. 13, 155–168.
Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B.,
Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003). Interleukin-23 rather
than interleukin-12 is the critical cytokine for autoimmune inflammation of the
brain. Nature 421, 744–748.
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. (2002).
Cancer immunoediting: from immunosurveillance to tumor escape. Nat.
Immunol. 3, 991–998.
Dunn, G.P., Bruce, A.T., Sheehan, K.C., Shankaran, V., Uppaluri, R., Bui, J.D.,
Diamond, M.S., Koebel, C.M., Arthur, C., White, J.M., and Schreiber, R.D.
(2005). A critical function for type I interferons in cancer immunoediting. Nat.
Immunol. 6, 722–729.
Garcia-Hernandez, M.L., Hernandez-Pando, R., Gariglio, P., and Berumen, J.
(2002). Interleukin-10 promotes B16-melanoma growth by inhibition of
macrophage functions and induction of tumour and vascular cell proliferation.
Immunology 105, 231–243.
Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., and
Trinchieri, G. (2002). Reciprocal activating interaction between natural killer
cells and dendritic cells. J. Exp. Med. 195, 327–333.
Ghilardi, N., Kljavin, N., Chen, Q., Lucas, S., Gurney, A.L., and De Sauvage,
F.J. (2004). Compromised humoral and delayed-type hypersensitivity
responses in IL-23-deficient mice. J. Immunol. 172, 2827–2833.
Grumont, R., Hochrein, H., O’Keeffe, M., Gugasyan, R., White, C., Caminschi,
I., Cook, W., and Gerondakis, S. (2001). c-Rel regulates interleukin 12 p70
expression in CD8(+) dendritic cells by specifically inducing p35 gene
transcription. J. Exp. Med. 194, 1021–1032.
Harris, T.J., Grosso, J.F., Yen, H.R., Xin, H., Kortylewski, M., Albesiano, E.,
Hipkiss, E.L., Getnet, D., Goldberg, M.V., Maris, C.H., et al. (2007). Cutting
edge: An in vivo requirement for STAT3 signaling in TH17 development and
TH17-dependent autoimmunity. J. Immunol. 179, 4313–4317.
Huber, M., Steinwald, V., Guralnik, A., Brustle, A., Kleemann, P., Rosenplanter,
C., Decker, T., and Lohoff, M. (2008). IL-27 inhibits the development of regula-
tory T cells via STAT3. Int. Immunol. 20, 223–234.
Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., and
Schreiber, R.D. (1998). Demonstration of an interferon gamma-dependent
tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci.
USA 95, 7556–7561.
Kinjyo, I., Inoue, H., Hamano, S., Fukuyama, S., Yoshimura, T., Koga, K.,
Takaki, H., Himeno, K., Takaesu, G., Kobayashi, T., and Yoshimura, A.
(2006). Loss of SOCS3 in T helper cells resulted in reduced immune responses
and hyperproduction of interleukin 10 and transforming growth factor-beta 1.
J. Exp. Med. 203, 1021–1031.
Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth,
M.J., and Schreiber, R.D. (2007). Adaptive immunitymaintains occult cancer in
an equilibrium state. Nature 450, 903–907.
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S.,
Niu, G., Kay, H., Mule, J., Kerr, W.G., et al. (2005). Inhibiting Stat3 signaling in
the hematopoietic system elicits multicomponent antitumor immunity. Nat.
Med. 11, 1314–1321.
Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J., Chang, A., and
Zou, W. (2007). Cutting edge: Th17 and regulatory T cell dynamics and the
regulation by IL-2 in the tumor microenvironment. J. Immunol. 178, 6730–
6733.
Langowski, J.L., Zhang, X.,Wu, L., Mattson, J.D., Chen, T., Smith, K., Basham,
B., McClanahan, T., Kastelein, R.A., and Oft, M. (2006). IL-23 promotes tumour
incidence and growth. Nature 442, 461–465.
Langowski, J.L., Kastelein, R.A., and Oft, M. (2007). Swords into plowshares:
IL-23 repurposes tumor immune surveillance. Trends Immunol. 28, 207–212.
Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedg-
wick, J.D., McClanahan, T., Kastelein, R.A., and Cua, D.J. (2005). IL-23 drives
a pathogenic T cell population that induces autoimmune inflammation. J. Exp.
Med. 201, 233–240.
Laurence, A., Tato, C.M., Davidson, T.S., Kanno, Y., Chen, Z., Yao, Z., Blank,
R.B., Meylan, F., Siegel, R., Hennighausen, L., et al. (2007). Interleukin-2
signaling via STAT5 constrains T helper 17 cell generation. Immunity 26,
371–381.
Murphy, C.A., Langrish, C.L., Chen, Y., Blumenschein, W., McClanahan, T.,
Kastelein, R.A., Sedgwick, J.D., and Cua, D.J. (2003). Divergent pro- and
antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
J. Exp. Med. 198, 1951–1957.
Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B., Vega, F.,
Yu, N., Wang, J., Singh, K., et al. (2000). Novel p19 protein engages
IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as
distinct from IL-12. Immunity 13, 715–725.
O’Shea, J.J., andMurray, P.J. (2008). Cytokine signalingmodules in inflamma-
tory responses. Immunity 28, 477–487.
Pallandre, J.R., Brillard, E., Crehange, G., Radlovic, A., Remy-Martin, J.P.,
Saas, P., Rohrlich, P.S., Pivot, X., Ling, X., Tiberghien, P., and Borg, C.
(2007). Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte genera-
tion: implications in graft-versus-host disease and antitumor immunity.
J. Immunol. 179, 7593–7604.
Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J.,
Pflanz, S., Zhang, R., Singh, K.P., Vega, F., et al. (2002). A receptor for the het-
erodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine
receptor subunit, IL-23R. J. Immunol. 168, 5699–5708.
Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J.,
and Schreiber, R.D. (2001). IFNgamma and lymphocytes prevent primary
tumour development and shape tumour immunogenicity. Nature 410, 1107–
1111.
Stumhofer, J.S., Silver, J.S., Laurence, A., Porrett, P.M., Harris, T.H., Turka,
L.A., Ernst, M., Saris, C.J., O’Shea, J.J., and Hunter, C.A. (2007). Interleukins
27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat.
Immunol. 8, 1363–1371.
Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N.,
Wildenberg, M.E., Allison, J.P., Toes, R.E., Offringa, R., and Melief, C.J.
(2001). Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade
and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alter-
native pathways for suppression of autoreactive cytotoxic T lymphocyte
responses. J. Exp. Med. 194, 823–832.
Takeda, K., Clausen, B.E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., and
Akira, S. (1999). Enhanced Th1 activity and development of chronic enteroco-
litis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10,
39–49.
Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and
adaptive immunity. Nat. Rev. Immunol. 3, 133–146.
Turk, M.J., Guevara-Patino, J.A., Rizzuto, G.A., Engelhorn, M.E., Sakaguchi,
S., and Houghton, A.N. (2004). Concomitant tumor immunity to a poorly
immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med.
200, 771–782.
122 Cancer Cell 15, 114–123, February 3, 2009 ª2009 Elsevier Inc.
Cancer Cell
Stat3 Regulates IL-23/IL-12 Balance in TumorsWan, Y.Y., and Flavell, R.A. (2007). Regulatory T-cell functions are subverted
and converted owing to attenuated Foxp3 expression. Nature 445, 766–770.
Wang, J., Wang, X., Hussain, S., Zheng, Y., Sanjabi, S., Ouaaz, F., and Beg,
A.A. (2007). Distinct roles of different NF-kappa B subunits in regulating inflam-
matory and T cell stimulatory gene expression in dendritic cells. J. Immunol.
178, 6777–6788.
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhatta-
charya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004). Regulation of
the innate and adaptive immune responses by Stat-3 signaling in tumor cells.
Nat. Med. 10, 48–54.
Wei, L., Laurence, A., Elias, K.M., andO’Shea, J.J. (2007). IL-21 is produced by
TH17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol.
Chem. 282, 34605–34610.
Yao, Z., Kanno, Y., Kerenyi, M., Stephens, G., Durant, L., Watford, W.T.,
Laurence, A., Robinson, G.W., Shevach, E.M., Moriggl, R., et al. (2007). Nonre-
dundant roles for Stat5a/b in directly regulating Foxp3. Blood 109, 4368–4375.
Yu, H., and Jove, R. (2004). The STATs of cancer–newmolecular targets come
of age. Nat. Rev. Cancer 4, 97–105.
Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and
immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immu-
nol. 7, 41–51.
Zheng, Y., Danilenko, D.M., Valdez, P., Kasman, I., Eastham-Anderson, J.,Wu,
J., and Ouyang, W. (2007). Interleukin-22, a T(H)17 cytokine, mediates
IL-23-induced dermal inflammation and acanthosis. Nature 445, 648–651.
Zhou, L., Ivanov, I.I., Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D.E.,
Leonard, W.J., and Littman, D.R. (2007). IL-6 programs T(H)-17 cell differenti-
ation by promoting sequential engagement of the IL-21 and IL-23 pathways.
Nat. Immunol. 8, 967–974.
Zorn, E., Nelson, E.A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci,
R., Raderschall, E., Canning, C., Soiffer, R.J., et al. (2006). IL-2 regulates
FOXP3 expression in human CD4+CD25+ regulatory T cells through a
STAT-dependent mechanism and induces the expansion of these cells
in vivo. Blood 108, 1571–1579.
Zou, W. (2005). Immunosuppressive networks in the tumour environment and
their therapeutic relevance. Nat. Rev. Cancer 5, 263–274.
Zou, W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat.
Rev. Immunol. 6, 295–307.Cancer Cell 15, 114–123, February 3, 2009 ª2009 Elsevier Inc. 123
